论文部分内容阅读
为了探讨索拉非尼对肝细胞癌患者TACE后血清VEGF水平的影响,选取50例初治的肝细胞癌患者,30例单行TACE治疗,20例行TACE后联合索拉非尼治疗。于TACE术前1d、术后1d及术后28d用双抗体夹心酶联免疫吸附试验法检测两组患者血清VEGF的水平。TACE术后1d两组患者血清VEGF浓度均较术前升高,差异有统计学意义(TACE组,P=0.02;索拉非尼组,P=0.00);术后28d,两组患者VEGF水平均降低,TACE联合索拉非尼患者血清VEGF浓度较单纯TACE组降低更明显,差异有统计学意义,P=0.00。初步研究结果提示,索拉非尼可降低原发性肝癌TACE后的VEGF水平。
In order to investigate the effect of sorafenib on serum VEGF level after TACE in hepatocellular carcinoma patients, 50 patients with newly diagnosed hepatocellular carcinoma, 30 TACE alone and 20 TACE combined with sorafenib were selected. Serum VEGF levels were measured at 1 day before TACE, 1 day after operation and 28 days after operation by double antibody sandwich enzyme-linked immunosorbent assay. The level of serum VEGF in the two groups at 1 day after TACE was significantly higher than that before operation (TACE group, P = 0.02; Sorafenib group, P = 0.00) Were lower, TACE combined with sorafenib serum VEGF concentrations decreased more significantly than the simple TACE group, the difference was statistically significant, P = 0.00. Preliminary results suggest that sorafenib can reduce the level of VEGF after TACE of primary liver cancer.